Junyuan Qi

Chinese Academy of Medical Sciences & Peking Union Medical College — China

Medicine · Health Sciences

17h-index1.3kcitations128works0.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(46), Lymphoma Diagnosis and Treatment(39), Multiple Myeloma Research and Treatments(28), Monoclonal and Polyclonal Antibodies Research(14), Chronic Myeloid Leukemia Treatments(10)

Publications128 total

A-319, a CD3xCD19 T cell engager, monotherapy for patients with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL)
Blood·2025
Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Blood·2025Open Access
Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study
Blood·2025Open Access
3112 – OVERCOMING DRUG RESISTANCE IN FLT3-ITD ACUTE MYELOID LEUKEMIA USING THE NOVEL FLT3 INHIBITOR XY0206
Experimental Hematology·2025
A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma.
Journal of Clinical Oncology·2025· 1 cited
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial
Cancer·2025· 5 citedOpen Access
Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial
Leukemia Research·2024
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Scientific Reports·2024Open Access
Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Blood·2024· 1 citedOpen Access
Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma
Blood·2024
Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor
Blood·2024Open Access
Patients with acquired pure red cell aplasia respond to <scp>PI3Kδ</scp> inhibitor rapidly
American Journal of Hematology·2024· 2 citedOpen Access
Abstract CT142: Phase 1 study of BPI-23314, a novel BET inhibitor and degrader, in advanced myeloid leukemia (AML)
Cancer Research·2024
Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China
Clinical Pharmacology in Drug Development·2024· 2 citedOpen Access
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors
Haematologica·2024· 3 citedOpen Access
Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results
Blood·2023· 2 cited
A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study
Blood·2023· 5 cited
A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
Blood·2023· 5 citedOpen Access
Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Blood·2023Open Access
Treatment with GT1708F, an Oral Smoothened Inhibitor, in Patients with Myeloid Malignancies: A Phase I Study
Blood·2023Open Access
page 1 of 7Next →

Frequent Co-authors

Lugui Qiu(19), Dehui Zou(17), Shuhua Yi(15), Zengjun Li(14), Gang An(13), Lugui Qiu(13), Jianxiang Wang(11), Yan Xu(9), Yaozhong Zhao(8), Weiwei Sui(7), Shuhui Deng(6), Mu Hao(6), Yaozhong Zhao(5), Tao Cheng(5), Kun Ru(5), Huilai Zhang(5), Hui Zhou(5), Jun Zhu(5), Keshu Zhou(5), Yuqin Song(5)